

## Optimizing Treatment Sequencing and Strategies

### References:

1. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet*. 2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-X
2. O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. *Br J Haematol*. 2018;182(2):222-230. doi:10.1111/bjh.15261
3. Zweegman S, et al. ASCO 2019. Abstract TPS8066. ClinicalTrials.gov Identifier: NCT03652064. Accessed February 24, 2022.
4. Facon T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. *N Engl J Med*. 2019;380:2104-2115.
5. Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. *Lancet Haematol*. 2022;9(11):e810-e821. doi:10.1016/S2352-3026(22)00263-0
6. Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. *Lancet Oncol*. 2021;22(12):1705-1720. doi:10.1016/S1470-2045(21)00535-0
7. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. *N Engl J Med*. 2022; 387:132-147. DOI: 10.1056/NEJMoa2204925
8. Lovas S, Obajed Al-Ali N, Varga G, et al. Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary. *Pathol Oncol Res*. 2022;28:1610645. Published 2022 Oct 3. doi:10.3389/pore.2022.1610645
9. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. *Hematology Am Soc Hematol Educ Program*. 2020;2020(1):248-258. doi:10.1182/hematology.2020000109

Provided by MediCom Worldwide, Inc.

Supported by educational grants from Bristol Myers Squibb Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.